Zydus Lifesciences, Apollo Hospitals Partner for Cancer Screening

MUMBAI — Zydus Lifesciences Limited has entered into a strategic memorandum of understanding (MoU) with Apollo Hospitals to broaden the availability of the ‘Shield’ multi-cancer detection (MCD) test in India. This partnership marks a significant development in the country's oncology landscape, as the two healthcare giants combine their distribution and clinical networks to facilitate early-stage cancer screening through a simple blood-based diagnostic tool.

The collaboration focuses on deploying the Shield test—developed by California-based precision oncology company Guardant Health—across Apollo’s extensive chain of hospitals and wellness centers. The initiative is specifically designed to address the high incidence of late-stage cancer diagnoses in India, where an estimated 60% to 70% of cases are currently detected only after the disease has advanced.

Enhancing Early Detection Capabilities

The Shield multi-cancer detection test utilizes advanced liquid biopsy technology to identify tumor-derived DNA fragments in the bloodstream. By detecting signals from multiple cancer types—including colorectal, lung, breast, pancreatic, liver, and gastric cancers—the test serves as a minimally invasive screening option that complements traditional diagnostic procedures.

According to industry data, early detection is critical for survival, with some studies suggesting that identifying malignancies in their initial stages can improve survival rates by three to ten times. By leveraging the combined strengths of Zydus Lifesciences’ pharmaceutical distribution and Apollo Hospitals’ clinical footprint, the partnership aims to make this cutting-edge screening technology accessible to a wider demographic across urban and semi-urban centers.

Strategic Shift Toward Preventive Oncology

The agreement with Apollo Hospitals extends an existing relationship between Zydus Lifesciences and Guardant Health, which began in 2023 with a focus on advanced-stage tumor diagnostics. While that initial phase targeted patients already undergoing cancer treatment, the new collaboration represents a paradigm shift toward "preventive oncology."

"Early detection through genomic profiling and liquid biopsy represents the future of cancer care in India," health experts noted. By integrating the Shield test into standard health check-ups at Apollo facilities, the initiative aims to bridge the gap in cancer screening participation, which remains low in the country compared to global standards.

Official Sources

According to company statements, Zydus Lifesciences will play a central role in the commercial rollout, coordinating with major hospital networks to establish the necessary diagnostic infrastructure. Organizers stated that the objective is to standardize the referral pathway for patients, ensuring that individuals who receive a positive result from the blood-based test are seamlessly transitioned to follow-up diagnostic procedures, such as colonoscopies or imaging, for confirmation.

Why It Matters

For citizens, the availability of the Shield test through Apollo Hospitals simplifies the screening process, removing the logistical hurdles often associated with specialized oncological testing. For the healthcare system, the widespread adoption of such screening tools is expected to reduce the long-term clinical and economic burden of treating late-stage cancers, which are significantly more expensive and complex to manage.

Key Facts at a Glance

• Test Technology: The 'Shield' MCD test uses liquid biopsy to detect circulating tumor DNA (ctDNA) from 10 common cancer types.

• Partnership: Zydus Lifesciences is facilitating the rollout, while Apollo Hospitals will provide the clinical infrastructure for patient access.

• Target Population: Individuals aged 45 or older at average risk for cancer, as well as those with specific risk factors.

• Clinical Goal: To increase early detection rates in a country where approximately 70% of cancers are caught at advanced stages.

FAQ

What specific cancers does the Shield test identify?

The panel is designed to detect signals for 10 cancer types, including colorectal, breast, lung, pancreatic, liver, esophageal, gastric, ovarian, prostate, and bladder cancer.

Is the Shield test a replacement for a colonoscopy?

No, it is a screening tool. A positive result indicates the presence of cancer signals, which must be confirmed by a diagnostic procedure, such as a colonoscopy, by a healthcare professional.

Where can patients access this test?

The rollout is being coordinated through Apollo Hospitals' network of facilities and associated laboratories in major Indian cities.

Source: Zydus Lifesciences, Apollo Hospitals, Guardant Health